Skip to main content
. 2019 Jun;67(6):740–754. doi: 10.4103/ijo.IJO_866_19

Table 3.

Intra-arterial chemotherapy- Worldwide Review Over Two Decades from 1998-2019

Authors (year, country) Years of study No. of eyes Total no. of catheterizations (% success rate) No. of sessions median (range) Drugs Indication (no.of eyes) Eye salvage in % Overall eye salvage in % Metastasis n (%) Death n (%) Complications Median follow up in months
Suzukiet al.12 (2011, Japan) 1998-2007 408 1469 (98.8) 3 (1-18) M Secondary 60* 60 8 (2) 12 (3) Periorbital swelling
Severe orbital cellulitis
Diffuse chorioretinal atrophy
Bradycardia
Bronchospasm
74
Gobinet al.23 (2011, USA) 2006-2010 95 259 (98.5) 3 (1-7) M, T, C Primary (39) Secondary (56) 82
58
70 2 (2) 0 (0) Periocular edema
Hyperemia
Avascular retinopathy
Cataract
Eyelash loss
13
Petersonet al.42 (2011, USA) 2008-2009 17 26 (100) 1.4 (1-2) M Secondary (17) 76.5 76.5 0 (0) 0 (0) Delayed vitreous hemorrhage 8.6 (mean)
Munieret al.43 (2011, Switzerland) 2009-2013 13 31 (96.8) 3 (1-3) M Primary (9) Secondary (4) 100
100
100 0 (0) 0 (0) Choroidal vasculopathy
Retinal detachment
Retinal arteriolar emboli
Vitreous hemorrhage
7 (mean)
Muenet al.45 (2012, UK) 2008-2010 15 NA 2 (1-3) M Secondary (15) 80 80 0 (0) 0 (0) Orbital edema
Forehead hyperemia
Retinal detachment
3rd cranial nerve palsy
RPE loss Epistaxis
Anaphylactoid reaction
7
Thampiet al.46 (2013, USA) 2010-2012 20 40 (100) 2.5 (1-5)* M Primary (12) Secondary (8) 66.5
87.5
70 0 (0) 0 (0) Eyelid edema/erythema
Dacryohemorrhea
Vitreous hemorrhage
Cataract
Choroid atrophy
OA spasm
Neutropenia
Bronchospasm
15*
Venturiet al.44 (2013, Italy) 2008-2010 39 146 (96) NA (1-9) M Primary (17) Secondary (24) 41
96
79 0 (0) 0 (0) Eyelid edema, hyperemia
Ptosis
Retinopathy
Strabismus
Lash loss
Frontal alopecia
Choroidal atrophy
Systemic toxicity
1-27
Shieldset al.25 (2014, USA) 2009-2013 70 198 (99.5) 3 (1-7) M, T, C Primary (36) Secondary (34) 72
62
67 0 (0) 0 (0) Eyelid edema
Blepheroptosis
Forehead hyperemia
Scalp alopecia
BRVO
Partial choroidal vascular
occlusion
Optic neuropathy
Vitreous hemorrhage
Phthisis bulbi
OA spasm
OA occlusion
19
Taichet al.47 (2014, Argentina) 2011-2013 27 66 (NA) NA M, T Primary (5) Secondary (22) 100
59
77.8 0 (0) 0 (0) 3rd cranial N. palsy
Hematological toxicity
11.7
Pararedaet al.48 (2014, Spain) 2008-2012 12 33 (94) 2.5 (1-5) M Primary (12) 58 58 0 (0) 0 (0) Diffuse arteriolar sclerosis
RPE hypertrophy
Partial retinal atrophy
OA spasm
29.5
Ghassemiet al.49 (2014, Iran) 2009-2012 24 NA 1-2 M, T, C Primary (6) Secondary (18) 84
56
62.5 0 (0) 0 (0) Eyelid edema
Vitreous hemorrhage
Choroidal ischemia
CRAO
Retinal hemorrhage
Retinal detachment
NVG
Ptosis
Retinal fibrosis
Cyclitic membrane
Phthisis
16.8
Onget al.50 (2015, Taiwan) 2010-2013 17 49 (91) 2.8 (1-6) Primary (6) Secondary (11) 66.5
54.5
59 3 (17.5) 2 (1) Lid edema
Retinal artery occlusion
Chorioretinal atrophy
Vitreous hemorrhage
3rd nerve palsy
6th nerve palsy
22
Akyuzet al.51 (2015, Turkey) 2011-2014 56 NA 2.3 (mean) 1-7 M Primary (44) Secondary (12) 75
64
66 2 (3.5) 2 (3.5) Transient eyelid swelling
Conjunctival chemosis
Ptosis
Forehead hyperemia
Ocular motility limitation
Mild proptosis
RPE alteration
Optic atrophy
Abramsonet al.24 (2016, USA) 2008-2015 120 418 (NA) 3.4 (mean) (1-11) M, T, C, Mtx Primary (60) Secondary (60) NA
NA
97 0 (0) 1 (0.8) Neutropenia 36
Tunceret al.52 (2016, Turkey) 2011-2015 24 76 (97.3) 3 (2-5) M, T, C Primary (Group D) 67 67 0 (0) 0 (0) Eyelid edema
Ptosis
Forehead hyperemia
Chorioretinal atrophy
Retinal detachment
Vitreous hemorrhage
29
Michaelset al.53 (2016, USA) 2008-2013 19 87 (100) 5 (mean) (2-10) M, T, C NA NA 58 0 (0) 0 (0) Localized erythema
Eyelid edema
Eyelash/brow loss
Forehead skin hyperpigmentation
Conjunctival chemosis
Neutropenia
Bronchospasm
Carboplatin anaphylaxis
13
Leal- Lealet al.54 (2016, Mexico) NA 11 NA 3 (all eyes) M, T Secondary 55 55 0 (0) 0 (0) Stroke
Nausea, vomitting
57 (mean)
Reddy MAet al.55 (2017, UK) 2013-2015 9 27 (NA) 3 (2-4) M, T Secondary 66 66 0 (0) 0 (0) Autonomic episode
Ptosis
Temporary 6th nerve palsy
Choroidal ischemia
21
Chenet al.56 (2017, China) 2011-2013 107 343 (98.5) 3.1 (2-5) M, T Primary (30) Secondary (77) 93
79
78.5 0 (0) 0 (0) Eyelid edema
Conjunctival congestion
Retinal hemorrhage
Vitreous hemorrhage
Retinal vasculopathy
OA spasm Transient myelosupression
13.6 (mean)
Rishiet al.56 (2017, India) 2013-2016 10 38 (NA) 4 (3-5) M, T Primary (2) Secondary (8) 100
75
80 0 (0) 0 (0) Forehead pigmentation
OA spasm
BRVO
Cataract
Optic atrophy
28
Ammanuelet al.58 (2018, USA) 2010-2017 43 125 (100) 2.8 M, T, C NA NA 35 0 (0) 0 (0) Stroke
Systemic toxicity
31.8
Hua Jet al.59 (2018, China) 2013-2015 84 200 (94.5) 2.8 (mean) M, T Secondary 30 30 0 (0) 0 (0) Eyelid edema
Vitreous hemorrhage
Retinal vasculopathy
OA spasm
Transient vomiting
Transient myelosupression
14.2 (mean)
Radroset al.60 (2018, Sweden) 2012-2015 11 39 (77) NA M NA 73 73 0 (0) 0 (0) Cerebrovascular emboli
Renal effects
Groin hematoma
Eyelid/periocular edema
Heterophoria
Exophthalmos
Ptosis
Periorbital erythema
OA spasm
Transient visual impairment
Papilledema
Retinal detachment
NA
Rojanapornet al.61 (2019, Thailand) 2009-2017 27 80 (94) 3 (1-7) M, T, C Primary (7) Secondary (20) 57
50
52 1 (3.7) 1 (3.7) TIA
Occlusive vasculopathy
Vitreous hemorrhage
Retinal artery precipitation
Strabismus
32 (mean)

*Calculated from the statistics available in the publication. M= melphalan; T= topotecan; C= carboplatin; Mtx= methotrexate; NA=not available; OA= ophthalmic artery; RPE= retinal pigment epithelium; CRAO= central retinal artery occlusion; NVG= neovascular glaucoma; BRVO= branch retinal vein occlusion; TIA= transient ischemic attack